Arrowhead Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-53.02	30.11	-609.69	-209.28	-176.49	-140.85
Depreciation & Amortization	32.19	23.93	18.6	12.49	10.42	8.27
Stock-Based Compensation	89.37	63.37	73.97	78.13	120.89	76.67
Other Adjustments	85.78	83.47	27.99	16.31	7.34	-1.44
Change in Receivables	-49.03	-56.97	-	1.41	8.85	-9.41
Changes in Inventories	-0.45	-	-	-	-	-
Changes in Accounts Payable	9.87	6.29	-5.54	33	-6.59	2.63
Changes in Accrued Expenses	4.83	41.5	32.12	-14.97	17.75	9.52
Changes in Unearned Revenue	103.36	2.4	-0.87	-129.18	-112.5	223.26
Changes in Other Operating Activities	-24.73	-14.54	0.58	58.19	-5.8	2.66
Operating Cash Flow	-59.06	179.55	-462.85	-153.89	-136.13	171.31
Operating Cash Flow Growth	-	-	-	-	-	-
Capital Expenditures	-16.06	-22.67	-141.47	-176.74	-52.78	-23.57
Purchases of Investments	-1,160	-796.26	-720.95	-246.14	-223.39	-240.7
Proceeds from Sale of Investments	325.9	689.63	442.34	326.72	270.75	122.59
Investing Cash Flow	-801.72	-129.29	-420.07	-96.16	-5.42	-141.68
Long-Term Debt Issued	3.16	10.26	392	-	-	-
Long-Term Debt Repaid	-117.89	-201.63	-	-	-	-
Net Long-Term Debt Issued (Repaid)	-114.73	-191.37	392	-	-	-
Issuance of Common Stock	236.21	270.37	431.65	3.05	5.19	11.31
Net Common Stock Issued (Repurchased)	236.21	270.37	431.65	3.05	5.19	11.31
Other Financing Activities	-18.72	-5	46.87	250	60	-
Financing Cash Flow	784.19	74.01	870.52	253.05	65.19	11.31
Foreign Exchange Rate Adjustments	1.56	-0.4	4.2	-0.12	-0.07	-0.09
Net Cash Flow	-76.59	124.26	-12.4	3.01	-76.36	40.94
Free Cash Flow	-75.11	156.89	-604.32	-330.63	-188.91	147.75
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-11.22%	18.91%	-17018.30%	-137.34%	-77.67%	106.84%
Free Cash Flow Per Share	-0.54	1.17	-5.05	-3.10	-1.79	1.42
Levered Free Cash Flow	-325.68	-156.1	-304.08	-422.48	-325.56	81.92
Unlevered Free Cash Flow	-135.44	94.37	-694.95	-424.97	-331.91	73.73

SEC Filings: 10-K · 10-Q